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1. INTRODUCTION {#jcmm15246-sec-0001}
===============

Coronary artery disease (CAD) is the leading cause of death both in developed and developing countries.[^1^](#jcmm15246-bib-0001){ref-type="ref"}, [^2^](#jcmm15246-bib-0002){ref-type="ref"} The aetiology of CAD remains obscure. Environmental and genetic factors, as well as the interactions between them, play a crucial role in the pathophysiology of CAD.[^3^](#jcmm15246-bib-0003){ref-type="ref"}, [^4^](#jcmm15246-bib-0004){ref-type="ref"} The heritability of CAD was estimated to range from 40%‐60% based on family and twin studies.[^5^](#jcmm15246-bib-0005){ref-type="ref"} Furthermore, the greatest genetic influence was observed on early‐onset CAD events,[^6^](#jcmm15246-bib-0006){ref-type="ref"} which implies a more vital role for genetic factors in determining CAD risk. Genotyping common single nucleotide polymorphisms (SNPs) within a potential CAD--related gene is an essential and efficient method to detect genetic risk markers, and many significant SNPs associated with CAD risk have been reported, such as *matrix metalloproteinase‐9*,[^7^](#jcmm15246-bib-0007){ref-type="ref"} *interleukin‐27* [^8^](#jcmm15246-bib-0008){ref-type="ref"} and *Toll‐like receptor 4*.[^9^](#jcmm15246-bib-0009){ref-type="ref"}

Inflammation plays a key role in the pathophysiology of CAD by promoting the development of atherosclerosis.[^10^](#jcmm15246-bib-0010){ref-type="ref"} As a pro‐inflammatory and immune‐regulatory cytokine, IL‐6 plays an important role in the genesis and maintenance of the inflammatory response in atherosclerosis. The *IL‐6* gene is located on chromosome 7p21‐24 and comprises 5 introns and 6 exons.[^11^](#jcmm15246-bib-0011){ref-type="ref"} Many SNPs in the *IL‐6* gene related to CAD risk have been reported, including *IL‐6*‐174G/C,[^12^](#jcmm15246-bib-0012){ref-type="ref"} *IL‐6*‐572C/G,[^13^](#jcmm15246-bib-0013){ref-type="ref"} *IL‐6*‐597G/A,[^14^](#jcmm15246-bib-0014){ref-type="ref"} *IL‐6*‐634C/G [^15^](#jcmm15246-bib-0015){ref-type="ref"} and *IL‐6*+2954G/C [^16^](#jcmm15246-bib-0016){ref-type="ref"}; however, some of them were not associated with CAD risk (IL6‐597G/A and +2954G/C) or only one study reported the increased risk of CAD (IL‐6‐634C/G). Among them, two common polymorphisms (*IL‐6* rs1800795 −174G/C and *IL‐6* rs1800796 −572C/G) have been extensively investigated; however, the results were inconclusive. Several previous studies have been conducted in an attempt to draw significant conclusions, but the limitations in sample size and potential false‐positive results caused by systematic errors may bias the results. We therefore performed a study to more accurately determine associations between *IL‐6* polymorphisms and CAD risk; in addition, the bioinformatics analysis was conducted to explore the potential molecular mechanism.

2. METHODS {#jcmm15246-sec-0002}
==========

2.1. Identification of the related studies {#jcmm15246-sec-0003}
------------------------------------------

A comprehensive document retrieval procedure was conducted to identify for all relevant studies published prior to October 2019. PubMed, Embase, VIP, Wan fang and China National Knowledge Infrastructure databases were thoroughly searched by the first three investigators to identify potential studies examining the associations between polymorphisms in the *interleukin‐6 (IL‐6)* gene and coronary artery disease. The terms 'coronary artery disease', 'coronary heart disease', 'myocardial infarction', 'CAD', 'heart disease', '*interleukin‐6', 'IL‐6*', 'polymorphism', 'variant' and 'polymorphisms' were used. The citations of review articles and all eligible studies were also browsed for additional potentially relevant study data. In addition, the language of the published studies was restricted to English.

2.2. Inclusion and exclusion criteria {#jcmm15246-sec-0004}
-------------------------------------

For inclusion in our analysis, studies must have met the following inclusion criteria: (a) evaluation of the relationship between the *IL‐6* polymorphisms and coronary artery disease; (b) coronary artery disease was defined as 50% stenosis in the left main coronary artery, or multiple significant (≥70% stenosis) in more than one coronary artery[^17^](#jcmm15246-bib-0017){ref-type="ref"}; (c) a case‐control or cohort design; (d) genotype distribution data were able to be acquired to calculate odds ratios (ORs) and 95% confidence intervals (CIs), particularly detailed data from the control group for testing Hardy‐Weinberg equilibrium. Exclusion criteria were as follows: (a) duplication of previous studies; (b) comments, reviews and editorials; (c) non‐English or non‐Chinese articles; and (d) studies lacking controls. Based on the inclusion and exclusion criteria, the first two authors independently reviewed the references and included the relevant studies. Any disagreement was solved by discussion with the third author (Wang).

2.3. Data extraction {#jcmm15246-sec-0005}
--------------------

For all included studies, the first two authors independently extracted the following data using a standardized form: first author\'s last name, year of publication, study country, study region, age and body mass index (BMI), source of the control population, genotyping method, sample size and genotype frequency of polymorphisms in the *IL6* gene in patients and controls. Disagreement was settled by rechecking the data or discussion with a third author.

2.4. Quality assessment {#jcmm15246-sec-0006}
-----------------------

The quality of the included studies was independently assessed by all the authors according to a set of criteria that were modified based on the Newcastle‐Ottawa quality assessment scale (Table [S1](#jcmm15246-sup-0001){ref-type="supplementary-material"}).

2.5. Statistical analysis {#jcmm15246-sec-0007}
-------------------------

Hardy‐Weinberg equilibrium (HWE) was tested in control groups from each study using the chi‐squared test, and *P* \< .05 was considered a significant departure from HWE. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the associations between *IL‐6* gene polymorphisms and coronary artery disease risk. Pooled ORs were calculated for the allelic model (*IL‐6* rs1800795: C versus G and *IL‐6* rs1800796: G versus C), recessive model (*IL‐6* rs1800795: CC versus CG + GG and *IL‐6* rs1800796: GG versus GC+CC), dominant model (*IL‐6* rs1800795: CC+CG versus GG and *IL‐6* rs1800796: GG+GC versus CC), heterozygote model (*IL‐6* rs1800795: CG versus GG and *IL‐6* rs1800796: GC versus CC) and homozygote model (*IL‐6* rs1800795: CC versus GG and *IL‐6* rs1800796: GG versus CC), respectively. Heterogeneity was evaluated using the Q statistic (significance level of *P* \< .1) and I^2^ statistic (greater than 50% as evidence of a significant inconsistency). Heterogeneity between studies was evaluated with the I^2^ test, and a higher I^2^ values indicated higher levels of heterogeneity (I^2^ \> 90%: extreme heterogeneity; I^2^ = 70% to 90%: substantial heterogeneity; I^2^ = 50% to 70%: moderate heterogeneity; I^2^ \< 50%: low heterogeneity). In the heterogeneity evaluation, the fixed‐effects model was used when I^2^ \< 50%, a random‐effects model was used if I^2^ = 50% to 90%, and the studies were not pooled if I2 \> 90%. A sensitivity analysis was performed to detect heterogeneity by sequentially omitting each study. Additionally, analyses were performed in subgroups stratified by accordance with HWE, region, ethnicity, source of controls and sample size. The potential for publication bias was assessed with Begg\'s funnel plot and Egger\'s test. We applied the Bonferroni method,[^18^](#jcmm15246-bib-0018){ref-type="ref"} which controls for the false discovery rate (FDR), to adjust for multiple comparisons. All tests reported in this study were conducted with the REVMAN 5.3 software and the STATA software (version 12.0; State Corporation).

2.6. Trial sequential analysis {#jcmm15246-sec-0008}
------------------------------

Systematic bias and random errors are inevitable when conducting a meta‐analysis because of the sparse data and repeated significance testing; moreover, trials with low methodological quality, publication bias and a small sample size may generate a false‐positive result. Trial sequential analysis (TSA) is an approach that provides the required amount of information (number of samples) and further reveals potentially false‐positive results in a meta‐analysis.[^19^](#jcmm15246-bib-0019){ref-type="ref"} Therefore, TSA was employed to calculate the required amount information for obtaining reliable data of our study.[^20^](#jcmm15246-bib-0020){ref-type="ref"}, [^21^](#jcmm15246-bib-0021){ref-type="ref"} The TSA was performed by anticipating a 10% relative risk reduction, an overall 5% risk of type I error and a statistical test power of 80%.

2.7. Bioinformatics analysis {#jcmm15246-sec-0009}
----------------------------

Ensembl is a genome browser for vertebrate genomes that supports research in comparative genomics, evolution, sequence variation and transcriptional regulation, and this database provides the genomic context, genes and regulatory elements, flanking sequence, population genetics, phenotype data, sample genotypes, linkage disequilibrium and phylogenetic context of a single nucleotide polymorphism (<http://asia.ensembl.org/index.html>). SNPinfo is an important bioinformatics analysis tool that predicts SNP function. The SNPinfo database can help researches specify genes or linkage regions and select SNPs based on GWAS results, calculate linkage disequilibrium (LD) and predict functional characteristics of both coding and non‐coding SNPs (<https://snpinfo.niehs.nih.gov/>).[^22^](#jcmm15246-bib-0022){ref-type="ref"} In addition, the RNAfold web server is one of the core programmes of the Vienna RNA package that has been used to predict the minimum free energy of single sequences that influence the stability of the structure.[^23^](#jcmm15246-bib-0023){ref-type="ref"} Therefore, we conducted bioinformatics analyses using the aforementioned databases and methods to identify the potential molecular mechanisms for further research.

3. RESULT {#jcmm15246-sec-0010}
=========

3.1. Characteristics of the included studies {#jcmm15246-sec-0011}
--------------------------------------------

The PRISMA flow diagram of our analysis was shown in Table [S2](#jcmm15246-sup-0002){ref-type="supplementary-material"}. Two hundred and thirty articles were retrieved by searching the international and Chinese databases. After removing duplicates and screening title and abstracts, 54 articles were subjected to the full‐text assessment and 12 articles were excluded due to the lack of detailed genotype distribution data. Finally, 37 articles[^12^](#jcmm15246-bib-0012){ref-type="ref"}, [^13^](#jcmm15246-bib-0013){ref-type="ref"}, [^14^](#jcmm15246-bib-0014){ref-type="ref"}, [^16^](#jcmm15246-bib-0016){ref-type="ref"}, [^24^](#jcmm15246-bib-0024){ref-type="ref"}, [^25^](#jcmm15246-bib-0025){ref-type="ref"}, [^26^](#jcmm15246-bib-0026){ref-type="ref"}, [^27^](#jcmm15246-bib-0027){ref-type="ref"}, [^28^](#jcmm15246-bib-0028){ref-type="ref"}, [^29^](#jcmm15246-bib-0029){ref-type="ref"}, [^30^](#jcmm15246-bib-0030){ref-type="ref"}, [^31^](#jcmm15246-bib-0031){ref-type="ref"}, [^32^](#jcmm15246-bib-0032){ref-type="ref"}, [^33^](#jcmm15246-bib-0033){ref-type="ref"}, [^34^](#jcmm15246-bib-0034){ref-type="ref"}, [^35^](#jcmm15246-bib-0035){ref-type="ref"}, [^36^](#jcmm15246-bib-0036){ref-type="ref"}, [^37^](#jcmm15246-bib-0037){ref-type="ref"}, [^38^](#jcmm15246-bib-0038){ref-type="ref"}, [^39^](#jcmm15246-bib-0039){ref-type="ref"}, [^40^](#jcmm15246-bib-0040){ref-type="ref"}, [^41^](#jcmm15246-bib-0041){ref-type="ref"}, [^42^](#jcmm15246-bib-0042){ref-type="ref"}, [^43^](#jcmm15246-bib-0043){ref-type="ref"}, [^44^](#jcmm15246-bib-0044){ref-type="ref"}, [^45^](#jcmm15246-bib-0045){ref-type="ref"}, [^46^](#jcmm15246-bib-0046){ref-type="ref"}, [^47^](#jcmm15246-bib-0047){ref-type="ref"}, [^48^](#jcmm15246-bib-0048){ref-type="ref"}, [^49^](#jcmm15246-bib-0049){ref-type="ref"}, [^50^](#jcmm15246-bib-0050){ref-type="ref"}, [^51^](#jcmm15246-bib-0051){ref-type="ref"}, [^52^](#jcmm15246-bib-0052){ref-type="ref"}, [^53^](#jcmm15246-bib-0053){ref-type="ref"}, [^54^](#jcmm15246-bib-0054){ref-type="ref"}, [^55^](#jcmm15246-bib-0055){ref-type="ref"}, [^56^](#jcmm15246-bib-0056){ref-type="ref"} were included in the qualitative and quantitative synthesis.

The characteristics of all included studies regarding the associations between *IL6* gene polymorphism and coronary artery disease are presented in Table [1](#jcmm15246-tbl-0001){ref-type="table"}. For the *IL‐6* rs1800795 polymorphism, 33 studies involving 9411 CAD patients and 3161 controls were included; 21 studies of 4720 patients with CAD and 5000 controls were included for the *IL‐6* rs1800796 polymorphism. Based on the modified Newcastle‐Ottawa Quality Assessment Scale, the score of each included study was greater than 7, which implied a sufficient methodological quality for analysis.

###### 

Characteristics of included studies

  Study                                                     Year   Country        Region          Age             BMI             Control        Genotyping     Sample   Case                                                     Control   Quality   HWE[\*](#jcmm15246-note-0005){ref-type="fn"}                               
  --------------------------------------------------------- ------ -------------- --------------- --------------- --------------- -------------- -------------- -------- -------------------------------------------------------- --------- --------- ---------------------------------------------- ----- ----- ----- ----- --- ------
  *IL6* rs1800795 polymorphism                                                                                                                                                                                                                                                                                                   
  Nauck[^24^](#jcmm15246-bib-0024){ref-type="ref"}          2002   Germany        Europe          63.77 ± 9.89    58.30 ± 11.83   27.52 ± 4.04   27.44 ± 4.34   HB       PCR‐RFLP                                                 3304      838       1238                                           499   230   355   144   8   .739
  Georges[^25^](#jcmm15246-bib-0025){ref-type="ref"}        2003   France         Europe          62 ± 10         61 ± 7          26.8 ± 3.6     26.6 ± 5.0     PB       PCR‐SSCP                                                 495       124       223                                            82    25    25    16    9   .064
  Yang[^26^](#jcmm15246-bib-0026){ref-type="ref"}           2004   China          Asian           55 ± 14         52 ± 18         26.0 ± 3.3     23.1 ± 2.8     HB       PCR‐RFLP                                                 295       110       2                                              0     179   4     0     8   .881
  Sekuri[^28^](#jcmm15246-bib-0028){ref-type="ref"}         2007   Turkey         Asian           46.3 ± 7.8      44.3 ± 7.2      26.5 ± 2.8     24.3 ± 2.6     PB       PCR‐RFLP                                                 220       61        49                                             5     57    41    7     8   .919
  Sarecka[^30^](#jcmm15246-bib-0030){ref-type="ref"}        2008   Poland         Europe          43.0 ± 5.5      42.3 ± 6.5      26.7 ± 4.4     25.4 ± 3.5     PB       PCR‐RFLP                                                 263       35        74                                             33    36    64    21    8   .413
  Banerjee[^31^](#jcmm15246-bib-0031){ref-type="ref"}       2009   India          Asian           56.3 ± 12.1     56.0 ± 9.5      NA             NA             HB       PCR‐RFLP                                                 442       159       43                                             8     171   57    4     9   .763
  Rios1[^47^](#jcmm15246-bib-0047){ref-type="ref"}          2010   Brazil         South America   55.7 ± 7.9      51.8 ± 8.4      NA             NA             HB       PCR‐TaqMan                                               253       96        36                                             6     69    43    3     8   .217
  Rios2[^47^](#jcmm15246-bib-0047){ref-type="ref"}          2010   Brazil         South America   55.7 ± 6.7      53.0 ± 7.7      NA             NA             HB       PCR‐TaqMan                                               414       158       90                                             28    82    46    10    9   .323
  Coker[^48^](#jcmm15246-bib-0048){ref-type="ref"}          2011   Turkey         Asian           53.4 ± 9.5      53.9 ± 9.3      28.4 ± 3.7     28.1 ± 3.6     PB       PCR‐RFLP                                                 402       102       56                                             9     141   81    13    9   .761
  Ghazouani[^33^](#jcmm15246-bib-0033){ref-type="ref"}      2011   Tunisia        Europe          58.1 ± 12.0     56.7 ± 14.12    27.08 ± 4.20   25.22 ± 2.35   HB       PCR‐RFLP                                                 824       298       110                                            10    297   102   7     9   .602
  Vakili[^49^](#jcmm15246-bib-0049){ref-type="ref"}         2011   Iran           Asian           NA              NA              NA             NA             PB       PCR‐TaqMan                                               900       153       234                                            63    202   229   19    9   .000
  Fan[^56^](#jcmm15246-bib-0056){ref-type="ref"}            2011   China          Asian           52.1 ± 6.8      52.3 ± 8.8      NA             NA             HB       PCR‐RFLP                                                 214       84        0                                              0     129   1     0     8   .965
  Liu[^34^](#jcmm15246-bib-0034){ref-type="ref"}            2011   China          Asian           60.6 ± 12.7     61.3 ± 13.7     NA             NA             HB       PCR‐RFLP                                                 276       123       3                                              0     148   2     0     8   .934
  Bhanushali[^35^](#jcmm15246-bib-0035){ref-type="ref"}     2013   India          Asian           48 ± 11         50 ± 11         NA             NA             HB       PCR‐SNaPshot[^a^](#jcmm15246-note-0004){ref-type="fn"}   250       77        20                                             3     121   25    4     8   .068
  Phulukdaree1[^36^](#jcmm15246-bib-0036){ref-type="ref"}   2013   South Africa   Africa          NA              NA              NA             NA             HB       PCR‐RFLP                                                 102       29        11                                             1     34    19    8     8   .062
  Phulukdaree2[^36^](#jcmm15246-bib-0036){ref-type="ref"}   2013   South Africa   Africa          NA              NA              NA             NA             HB       PCR‐RFLP                                                 120       38        16                                             5     34    19    8     8   .062
  Satti[^38^](#jcmm15246-bib-0038){ref-type="ref"}          2013   Pakistan       Asian           46.4 ± 18.7     35.2 ± 17.4     25.9 ± 3.5     25.2 ± 3.5     PB       PCR‐RFLP                                                 88        18        11                                             7     38    14    0     7   .262
  Tong[^50^](#jcmm15246-bib-0050){ref-type="ref"}           2013   China          Asian           61.4 ± 8.7      60.6 ± 9.6      23.2 ± 3.1     22.7 ± 2.8     HB       PCR‐TaqMan                                               667       201       87                                             38    220   98    23    9   .011
  Zhang[^37^](#jcmm15246-bib-0037){ref-type="ref"}          2013   China          Asian           NA              NA              NA             NA             HB       PCR‐HRM                                                  506       221       10                                             0     264   11    0     9   .735
  Elsaid[^51^](#jcmm15246-bib-0051){ref-type="ref"}         2014   Egypt          Africa          53.54 ± 9.1     45.3 ± 7.2      NA             NA             PB       PCR‐TaqMan                                               208       26        55                                             23    0     49    55    8   .000
  Galimudi[^39^](#jcmm15246-bib-0039){ref-type="ref"}       2014   India          Asian           65 ± 5          64 ± 6          NA             NA             PB       PCR‐RFLP                                                 400       72        102                                            26    113   69    18    9   .123
  Hatzis1[^40^](#jcmm15246-bib-0040){ref-type="ref"}        2014   Greece         Europe          NA              NA              NA             NA             HB       PCR‐RFLP                                                 361       109       76                                             12    64    72    28    9   .733
  Hatzis2[^40^](#jcmm15246-bib-0040){ref-type="ref"}        2014   Greece         Europe          NA              NA              NA             NA             HB       PCR‐RFLP                                                 285       36        71                                             43    67    57    11    8   .817
  Sun[^14^](#jcmm15246-bib-0014){ref-type="ref"}            2014   China          Asian           61.2 ± 8.5      56.4 ± 11.6     NA             NA             HB       PCR‐TaqMan                                               623       191       61                                             44    236   63    28    9   .000
  Celik[^16^](#jcmm15246-bib-0016){ref-type="ref"}          2015   Turkey         Asian           14.56 ± 1.73    13.91 ± 1.31    20.29 ± 3.59   19.78 ± 3.25   HB       PCR‐RFLP                                                 82        24        12                                             0     29    16    1     7   .476
  Li[^41^](#jcmm15246-bib-0041){ref-type="ref"}             2015   China          Asian           NA              NA              NA             NA             HB       PCR‐RFLP                                                 730       213       113                                            39    245   105   15    9   .382
  Wang 42                                                   2015   China          Asian           65.4 ± 8.4      64.9 ± 8.2      22.8 ± 2.9     22.6 ± 2.6     HB       PCR‐RFLP                                                 804       153       171                                            78    176   187   39    9   .292
  Yang[^43^](#jcmm15246-bib-0043){ref-type="ref"}           2015   China          Asian           NA              NA              NA             NA             HB       PCR‐RFLP                                                 820       198       163                                            49    239   146   25    9   .669
  Hongmei[^12^](#jcmm15246-bib-0012){ref-type="ref"}        2016   China          Asian           62.64 ± 8.43    61.43 ± 7.85    26.41 ± 2.56   25.75 ± 2.54   HB       PCR‐RFLP                                                 571       256       19                                             0     282   14    0     8   .679
  Mao[^52^](#jcmm15246-bib-0052){ref-type="ref"}            2016   China          Asian           62.65 ± 9.72    56.82 ± 9.80    24.61 ± 4.16   21.57 ± 3.64   HB       PCR‐RFLP                                                 584       142       45                                             37    267   63    30    7   .000
  Jabir[^53^](#jcmm15246-bib-0053){ref-type="ref"}          2017   Saudi Arabia   Asian           60.6 ± 8.85     47.7 ± 5.06     28.69 ± 4.34   30.89 ± 2.90   HB       PCR‐TaqMan                                               179       62        25                                             3     63    23    3     8   .620
  Mitrokhin[^54^](#jcmm15246-bib-0054){ref-type="ref"}      2017   Russian        Europe          70.37 ± 13.45   74.94 ± 7.43    30.71 ± 2.75   30.33 ± 6.09   HB       PCR‐TaqMan                                               314       62        100                                            36    32    58    26    9   .977
  Chen[^55^](#jcmm15246-bib-0055){ref-type="ref"}           2018   China          Asian           61.00 ± 10.49   60.37 ± 10.38   25.13 ± 8.12   23.47 ± 8.72   HB       Multiplex PCR                                            779       155       218                                            56    190   133   27    9   .581
  *IL6* rs1800796 polymorphism                                                                                                                                                                                                    CC        CG        GG                                             CC    CG    GG               
  Fu[^45^](#jcmm15246-bib-0045){ref-type="ref"}             2006   China          Asian           61.8 ± 12.4     59.89 ± 14.35   NA             NA             HB       PCR‐RFLP                                                 505       128       101                                            16    166   90    4     7   .034
  Wei[^27^](#jcmm15246-bib-0027){ref-type="ref"}            2006   China          Asian           61 ± 11         60 ± 10         NA             NA             HB       PCR‐RFLP                                                 335       89        67                                             9     113   55    2     8   .095
  Gao[^29^](#jcmm15246-bib-0029){ref-type="ref"}            2008   China          Asian           65.2 ± 9.8      62.5 ± 11.8     NA             NA             HB       PCR‐RFLP                                                 234       65        51                                             10    72    32    4     8   .850
  Jia[^46^](#jcmm15246-bib-0046){ref-type="ref"}            2010   China          Asian           NA              NA              NA             NA             HB       PCR                                                      441       79        130                                            22    88    107   15    7   .021
  Liang[^32^](#jcmm15246-bib-0032){ref-type="ref"}          2010   China          Asian           57.6 ± 7.4      56.4 ± 8.2      26.4 ± 3.1     24.2 ± 2.6     HB       PCR‐RFLP                                                 851       259       161                                            14    283   126   8     8   .156
  Fan[^56^](#jcmm15246-bib-0056){ref-type="ref"}            2011   China          Asian           52.1 ± 6.8      52.3 ± 8.8      NA             NA             HB       PCR‐RFLP                                                 214       42        38                                             4     95    32    3     8   .875
  Liu[^34^](#jcmm15246-bib-0034){ref-type="ref"}            2011   China          Asian           60.6 ± 12.7     61.3 ± 13.7     NA             NA             HB       PCR‐RFLP                                                 276       63        52                                             11    92    55    3     9   .107
  Coker 48                                                  2011   Turkey         Asian           53.4 ± 9.5      53.9 ± 9.3      28.4 ± 3.7     28.1 ± 3.6     PB       PCR‐RFLP                                                 402       126       30                                             11    169   45    21    7   .000
  Zhang[^37^](#jcmm15246-bib-0037){ref-type="ref"}          2013   China          Asian           NA              NA              NA             NA             HB       PCR‐HRM                                                  506       86        106                                            39    128   117   30    9   .675
  Tong[^50^](#jcmm15246-bib-0050){ref-type="ref"}           2013   China          Asian           61.4 ± 8.8      60.6 ± 9.7      23.2 ± 3.2     22.7 ± 2.9     HB       PCR‐TaqMan                                               667       179       110                                            37    180   120   41    7   .004
  Sun[^14^](#jcmm15246-bib-0014){ref-type="ref"}            2014   China          Asian           61.2 ± 8.5      56.4 ± 11.6     NA             NA             HB       PCR‐TaqMan                                               623       190       69                                             37    215   73    39    7   .000
  Wang[^42^](#jcmm15246-bib-0042){ref-type="ref"}           2015   China          Asian           65.4 ± 8.4      64.9 ± 8.2      22.8 ± 2.9     22.6 ± 2.6     HB       PCR‐RFLP                                                 804       176       187                                            39    192   181   29    9   .119
  Li[^41^](#jcmm15246-bib-0041){ref-type="ref"}             2015   China          Asian           NA              NA              NA             NA             HB       PCR‐RFLP                                                 729       132       165                                            68    166   155   43    9   .462
  Fragoso[^13^](#jcmm15246-bib-0013){ref-type="ref"}        2015   Mexico         South America   NA              NA              NA             NA             HB       PCR‐TaqMan                                               244       7         39                                             32    11    77    78    8   .163
  Celik[^16^](#jcmm15246-bib-0016){ref-type="ref"}          2015   Turkey         Asian           14.56 ± 1.73    13.91 ± 1.31    20.29 ± 3.59   19.78 ± 3.25   HB       PCR‐RFLP                                                 82        25        10                                             1     42    3     1     7   .013
  Mao[^52^](#jcmm15246-bib-0052){ref-type="ref"}            2016   China          Asian           62.65 ± 9.72    56.82 ± 9.80    24.61 ± 4.16   21.57 ± 3.64   HB       PCR‐RFLP                                                 584       97        110                                            17    147   176   37    8   .137
  Hongmei[^12^](#jcmm15246-bib-0012){ref-type="ref"}        2016   China          Asian           62.64 ± 8.43    61.43 ± 7.85    26.41 ± 2.56   25.75 ± 2.54   HB       PCR‐RFLP                                                 572       87        134                                            55    135   129   32    8   .886
  Chen[^44^](#jcmm15246-bib-0044){ref-type="ref"}           2016   China          Asian           63.22 ± 9.40    53.81 ± 8.45    NA             NA             HB       PCR‐RFLP                                                 399       72        98                                             27    108   83    11    8   .333
  Jabir[^53^](#jcmm15246-bib-0053){ref-type="ref"}          2017   Saudi Arabia   Asian           60.6 ± 8.85     47.7 ± 5.06     28.69 ± 4.34   30.89 ± 2.90   HB       PCR‐TaqMan                                               159       3         22                                             59    0     21    54    8   .159
  Mitrokhin[^54^](#jcmm15246-bib-0054){ref-type="ref"}      2017   Russian        Europe          70.37 ± 13.45   74.94 ± 7.43    30.71 ± 2.75   30.33 ± 6.09   HB       PCR‐TaqMan                                               314       0         16                                             182   2     10    104   7   .010
  Chen[^55^](#jcmm15246-bib-0055){ref-type="ref"}           2018   China          Asian           61.00 ± 10.49   60.37 ± 10.38   25.13 ± 8.12   23.47 ± 8.72   HB       Multiplex PCR                                            779       228       158                                            43    176   141   33    9   .539

For rs1800795 polymorphism, XX, XY and YY represent GG, GC and CC, respectively; for rs1800796 polymorphism, XX, XY and YY represent CC, CG and GG, respectively.

Abbreviations: BMI, body mass index; CAD, coronary artery disease; HB, hospital based; NA, not available; PB, population based; PCR, polymorphism chain reaction‐restriction; PCR‐HRM, polymorphism chain reaction high‐resolution melting; PCR‐RFLP, polymorphism chain reaction‐restriction fragment length polymorphism; PCR‐SSCP, polymorphism chain reaction single‐strand conformation polymorphism; PCR‐TaqMan, polymorphism chain reaction‐restriction TaqMan polymorphism.

The polymorphism was determined by a variation of the allele termination assay reported by Bhanushali et al[^35^](#jcmm15246-bib-0035){ref-type="ref"}

*P* value for Hardy‐Weinberg equilibrium test in controls.
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3.2. The pooled analysis of *IL‐6* polymorphisms and CAD risk {#jcmm15246-sec-0012}
-------------------------------------------------------------

The main results of our analysis and the heterogeneity test of the associations between *IL‐6* gene polymorphisms and coronary artery disease risk are shown in Table [2](#jcmm15246-tbl-0002){ref-type="table"}. In the pooled analysis, no significant association was observed for the *IL‐6* rs1800795 polymorphism; significant associations with heterogeneity were detected in all five genetic models for the *IL‐6* rs1800796 polymorphism: allelic genetic model (OR \[95% CI\] = 1.28 \[1.13, 1.44\], *P* = 2^\*^10^−4^), dominant genetic model (OR \[95% CI\] = 1.35 \[1.17, 1.57\], *P* = 2^\*^10^−4^), heterogeneity genetic model (OR \[95% CI\] = 1.26 \[1.15, 1.37\], *P* = 2^\*^10^−4^), recessive genetic model (OR \[95% CI\]=1.35 \[1.18, 1.55\], *P* = 2^\*^10^−4^ (Figure [1](#jcmm15246-fig-0001){ref-type="fig"})) and homozygote genetic model (OR \[95% CI\] = 1.62 \[1.23, 2.13\], *P* = .001).

###### 

Pooled and Subgroup analysis of the associations between IL‐6 polymorphisms and CAD risk

  Subgroup analysis                                            No. of the studies   Allelic genetic model     Dominant genetic model              Recessive genetic model   Heterozygote genetic model   Homozygote genetic model                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------ -------------------- ------------------------- ----------------------------------- ------------------------- ---------------------------- ----------------------------------- --------------------- ------------------------- ----------------------------------- -------------------------- ------------------------- ----------------------------------- ----------------- ------------------------- ----------------------------------- ---------------------
  *IL6* rs1800795 polymorphism                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Pooled results                                               33                   1.40 \[1.12, 1.75\]       .003/.015/.015                      2\*10^−4^/93%/R           1.21 \[1.05, 1.40\]          .01/.050/.0167                      2\*10^−4^/69%/R       1.34 \[1.02, 1.76\]       .04/.200/.040                       2\*10^−4^/78%/R            1.15 \[1.01, 1.30\]       .03/.150/.038                       2\*10^−4^/54%/R   1.48 \[1.10, 2.00\]       .01/.050/.017                       2\*10^−4^/78%/R
  *Subgroup Results*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  HWE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  In accordance with HWE                                       28                   1.31 \[1.08, 1.59\]       .007/.035/.035                      2\*10^−4^/88%/R           1.18 \[1.00, 1.39\]          .04/.200/.060                       2\*10^−4^/69%/R       1.30 \[0.99, 1.72\]       .06/.300/.060                       2\*10^−4^/69%/R            1.15 \[0.99, 1.32\]       .06/.300/.060                       2\*10^−4^/55%/R   1.40 \[1.01, 1.94\]       .04/.200/.060                       2\*10^−4^/75%/R
  Departure from HWE                                           5                    1.97 \[1.01, 3.85\]       .05/.25/.20                         2\*10^−4^/97%/R           1.34 \[0.96, 1.88\]          .09/.45/.20                         .005/73%/R            1.49 \[0.65, 3.40\]       .35/1.00/.41                        2\*10^−4^/92%/R            1.14 \[0.83, 1.58\]       .41/1.00/.41                        .03/63%/R         1.79 \[0.86, 3.74\]       .12/.60/.20                         2\*10^−4^/84%/R
  Region                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Asian                                                        21                   1.84 \[1.42, 2.39\]       2\*10^−4^/2\*10^−4^/2\*10^−4^       2\*10^−4^/91%/R           **1.40 \[1.24, 1.58\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.05/36%/R**         **1.99 \[1.63, 2.42\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.20/22%/R**              **1.26 \[1.11, 1.43\]**   **2\*10^−4^/.002/2\*10^−4^**        **.10/30%/R**     **2.21 \[1.78, 2.73\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.14/28%/R**
  Europe                                                       7                    1.20 \[0.87, 1.65\]       .27/1/.800                          2\*10^−4^/90%/R           1.13 \[0.80, 1.59\]          .48/1/.800                          2\*10^−4^/82%/R       1.05 \[0.65, 1.69\]       .84/1/.840                          2\*10^−4^/81%/R            1.11 \[0.85, 1.46\]       .43/1/.800                          .005/67%/R        1.15 \[0.62, 2.11\]       .66/1/.825                          2\*10^−4^/86%/R
  Africa                                                       3                    **0.45 \[0.26, 0.77\]**   **.004/.02/.01**                    **.06/64%/R**             0.33 \[0.08, 1.33\]          .12/.60/.15                         .009/79%/R            **0.29 \[0.17, 0.50\]**   **2\*10^−4^/.00/.00**               **.37/1%/R**               0.41 \[0.11, 1.58\]       .20/1.00/.20                        .02/74%/R         0.11 \[0.01, 1.37\]       .09/.45/.15                         0.009/79%/R
  South America                                                2                    0.97 \[0.67, 1.41\]       .88/1/.880                          .17/46%/R                 0.87 \[0.53, 1.43\]          .58/1/.725                          .13/56%/R             1.50 \[0.77, 2.91\]       .23/1/.650                          .84/0%/R                   0.80 \[0.48, 1.33\]       .39/1/.650                          .14/53%/R         1.45 \[0.74, 2.85\]       .28/1/.650                          .99/0%/R
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Caucasian                                                    17                   1.44 \[1.10, 1.90\]       .009/.045/.045                      2\*10^−4^/93%/R           1.20 \[0.98, 1.47\]          .07/.350/.150                       2\*10^−4^/73%/R       1.27 \[0.89, 1.81\]       .18/.900/.180                       2\*10^−4^/74%/R            1.15 \[0.98, 1.37\]       .09/.450/.150                       .003/56%/R        1.40 \[0.92, 2.14\]       .12/.600/.150                       2\*10^−4^/79%/R
  Mongoloid                                                    12                   1.97 \[1.44, 2.70\]       2\*10^−4^/2\*10^−4^/2\*10^−4^       2\*10^−4^/90%/R           **1.47 \[1.31, 1.65\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.40/4%/R**          **2.07 \[1.72, 2.50\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.94/0%/R**               **1.28 \[1.11, 1.49\]**   **.001/.004/2\*10^−4^**             **.24/21%/R**     **2.28 \[1.87, 2.77\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.92/0%/R**
  African                                                      4                    0.52 \[0.32, 0.86\]       .01/.05/.050                        .01/72%/R                 0.49 \[0.23, 1.05\]          .07/.35/.125                        .03/66%/R             0.46 \[0.18, 1.17\]       .10/.50/.125                        .06/59%/R                  0.55 \[0.28, 1.11\]       .10/.50/.125                        .08/56%/R         0.24 \[0.03, 1.61\]       .14/.70/.140                        .003/79%/R
  Source of Controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Hospital based                                               25                   1.48 \[1.14, 1.94\]       .004/.020/.020                      2\*10^−4^/94%/R           1.16 \[0.99, 1.35\]          .07/.350/.088                       2\*10^−4^/68%/R       **1.46 \[1.10, 1.94\]**   **.009/.045/.0225**                 **2**\*10^−4^ **/72%/R**   1.10 \[0.96, 1.25\]       .18/.900/.180                       .004/48%/R        1.50 \[1.08, 2.09\]       .02/.100/.033                       2\*10^−4^/78%/R
  Population based                                             8                    1.18 \[0.78, 1.80\]       .43/1.0/.5375                       2\*10^−4^/91%/R           1.39 \[0.98, 1.96\]          .06/.3/.200                         .001/72%/R            1.17 \[0.57, 2.40\]       .68/1.0/.6800                       2\*10^−4^/87%/R            1.34 \[0.97, 1.84\]       .08/.4/.200                         .007/64%/R        1.37 \[0.64, 2.92\]       .41/1.0/.538                        2\*10^−4^/81%/R
  Sample size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Less than 300                                                14                   1.21 \[0.68, 2.18\]       .52/1.0/.97                         2\*10^−4^/93%/R           1.05 \[0.72, 1.54\]          .80/1.0/.97                         2\*10^−4^/68%/R       1.02 \[0.47, 2.21\]       .97/1.0/.97                         2\*10^−4^/79%/R            1.04 \[0.77, 1.41\]       .80/1.0/.97                         .03/46%/R         1.04 \[0.77, 1.41\]       .94/1.0/.97                         2\*10^−4^/78%/R
  Between 300 and 500                                          7                    1.11 \[0.80, 1.53\]       .54/1.0/.99                         2\*10^−4^/85%/R           1.05 \[0.73, 1.51\]          .80/1.0/.99                         2\*10^−4^/79%/R       0.92 \[0.59, 1.43\]       .71/1.0/.99                         .02/61%/R                  1.08 \[0.76, 1.54\]       .66/1.0/.99                         .001/75%/R        1.08 \[0.76, 1.54\]       .99/1.0/.99                         .001/73%/R
  More than 500                                                12                   **1.81 \[1.33, 2.45\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/95%/R**       **1.37 \[1.17, 1.59\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.001/64%/R**        **1.95 \[1.42, 2.67\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/78%/R**        **1.22 \[1.06, 1.40\]**   **.004/2\*10^−4^/.004**             **.03/48%/R**     **1.22 \[1.06, 1.40\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/80%/R**
  *IL6* rs1800796 polymorphism                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Pooled results                                               21                   **1.28 \[1.13, 1.44\]**   **2\*10^−4^/.001/2\*10^−4^**        **2\*10^−4^/68%/R**       **1.35 \[1.17, 1.57\]**      **2\*10^−4^/.001/2\*10^−4^**        **2\*10^−4^/62%/R**   **1.35 \[1.18, 1.55\]**   **2\*10^−4^/.001/2\*10^−4^**        **.01/46%/F**              **1.26 \[1.15, 1.37\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.001/47%/F**    **1.62 \[1.23, 2.13\]**   **.001/.003/.001**                  **2\*10^−4^/60%/R**
  *Subgroup results*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  HWE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  In accordance with HWE                                       14                   **1.32 \[1.15, 1.53\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/70%/R**       **1.42 \[1.19, 1.69\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.001/62%/R**        **1.48 \[1.15, 1.91\]**   **.002/2\*10^−4^/.0020**            **.02/50%/R**              **1.33 \[1.14, 1.55\]**   **2\*10^−4^/2\*10^−4^/.001**        **.02/49%/R**     **1.78 \[1.28, 2.47\]**   **.001/2\*10^−4^/.001**             **.002/60%/R**
  Departure from HWE                                           7                    1.18 \[0.94, 1.47\]       .15/.75/.283                        .01/63%/R                 1.22 \[0.92, 1.62\]          .16/.80/.283                        .02/60%/R             1.16 \[0.84, 1.61\]       .37/1.00/.370                       .21/29%/R                  1.20 \[0.92, 1.56\]       .17/.85/.283                        .07/48%/R         1.31 \[0.82, 2.07\]       .26/1.00/.325                       .06/51%/R
  Region                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Asian                                                        19                   **1.30 \[1.15, 1.47\]**   **2\*10^−4^/.001/2\*10^−4^**        **2\*10^−4^/69%/R**       **1.36 \[1.17, 1.58\]**      **2\*10^−4^/.001/2\*10^−4^**        **2\*10^−4^/63%/R**   **1.44 \[1.16, 1.78\]**   **.001/.005/.001**                  **.02/45%/R**              **1.29 \[1.13, 1.48\]**   **2\*10^−4^/.001/2\*10^−4^**        **.008/50%/R**    **1.66 \[1.26, 2.19\]**   **2\*10^−4^/.002/2\*10^−4^**        **2\*10^−4^/61%/R**
  South America[^a^](#jcmm15246-note-0008){ref-type="fn"}      1                    0.83 \[0.55, 1.24\]       .36/1.0/.6375                       NA                        0.72 \[0.27, 1.93\]          .51/1.0/.638                        NA                    0.78 \[0.46, 1.35\]       .38/1.0/.638                        NA                         0.80 \[0.29, 2.21\]       .66/1.0/.660                        NA                0.64 \[0.23, 1.81\]       .4/1.0/.638                         NA
  Europe[^a^](#jcmm15246-note-0008){ref-type="fn"}             1                    1.53 \[0.73, 3.19\]       .26/1.0/.325                        NA                        8.67 \[0.41, 182.13\]        .16/.8/.325                         NA                    1.31 \[0.60, 2.88\]       .5/1.0/0.5                          NA                         7.86 \[0.34, 180.34\]     .2/1.0/.325                         NA                8.73 \[0.42, 183.62\]     .16/.8/.325                         NA
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Caucasian                                                    16                   **1.33 \[1.17, 1.50\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/68%/R**       **1.38 \[1.19, 1.59\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.001/62%/R**        **1.54 \[1.23, 1.93\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.02/47%/R**              **1.30 \[1.14, 1.47\]**   **2\*10^−4^/2\*10^−4^/.0001**       **.02/46%/R**     **1.78 \[1.34, 2.36\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/62%/R**
  Mongoloid                                                    5                    1.02 \[0.71, 1.48\]       .90/1.0/.90                         .08/52%/R                 1.23 \[0.50, 3.04\]          .65/1.0/.813                        .04/61%/R             0.88 \[0.63, 1.23\]       .47/1.0/.813                        .82/0%/R                   1.31 \[0.52, 3.30\]       .57/1.0/.813                        .05/58%/R         0.73 \[0.41, 1.31\]       .30/1.0/.813                        .41/0%/R
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Hospital based                                               20                   **1.30 \[1.16, 1.47\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/67%/R**       **1.39 \[1.19, 1.61\]**      **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **2\*10^−4^/61%/R**   **1.42 \[1.16, 1.74\]**   **.001/2\*10^−4^/.001**             **.02/44%/R**              **1.31 \[1.14, 1.50\]**   **2\*10^−4^/2\*10^−4^/.002**        **.01/47%/R**     **1.70 \[1.29, 2.24\]**   **2\*10^−4^/2\*10^−4^/2\*10^−4^**   **.001/58%/R**
  Population based[^a^](#jcmm15246-note-0008){ref-type="fn"}   1                    0.81 \[0.56, 1.18\]       .28/1.0/.5375                       NA                        0.83 \[0.53, 1.31\]          .43/1.0/.538                        NA                    0.72 \[0.34, 1.53\]       .39/1.0/.538                        NA                         0.89 \[0.53, 1.50\]       .67/1.0/.670                        NA                0.70 \[0.33, 1.51\]       .37/1.0/.538                        NA
  Sample size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Less than 300                                                6                    1.46 \[0.99, 2.14\]       .05/.25/.083                        .005/71%/R                1.46 \[0.99, 2.14\]          .01/.05/.050                        .07/52%/R             1.37 \[0.78, 2.40\]       .28/1.00/.280                       .12/42%/R                  1.71 \[1.06, 2.77\]       .03/ .15/.075                       .06/52%/R         1.75 \[0.71, 4.31\]       .22/1.00/.275                       .08/50%/R
  Between 300 and 500                                          5                    1.35 \[1.01, 1.80\]       .04/.20/.067                        .02/66%/R                 1.35 \[1.01, 1.80\]          .04/.20/.067                        .04/60%/R             1.56 \[0.90, 2.69\]       .11/.55/.110                        .07/54%/R                  1.40 \[1.07, 1.83\]       .01/.05/.050                        .24/27%/R         2.17 \[0.95, 4.93\]       .06/.30/.075                        .01/68%/R
  More than 500                                                10                   **1.21 \[1.05, 1.39\]**   **.008/.04/.010**                   **.001/70%/R**            1.21 \[1.05, 1.39\]          .01/.05/.013                        .006/61%/R            1.36 \[1.07, 1.74\]       .01/.05/.013                        .03/50%/R                  1.18 \[1.03, 1.35\]       .02/.10/.020                        .10/38%/R         1.48 \[1.09, 2.01\]       .01/.05/.013                        .002/65%/R

Results with *P* \< .05 even after the Bonferroni adjusted and a tolerable heterogeneity (I2 \< 85%) were regarded as significant.

Abbreviations: BMI, body mass index; CI, confidence interval; EM, effect model; F, fixed effect model; OR, odds ratio; *P*1, *P* value for meta‐analysis; *P*2, *P* value for heterogeneity test; R, random effect model.

Only one study was included in the subgroup, and heterogeneity was not applicable.

Results with *P* \< .05 even after the Bonferroni adjusted and a tolerable heterogeneity (I2 \< 85%)
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![IL‐6 rs1800795 polymorphism (Recessive genetic model)](JCMM-24-6191-g001){#jcmm15246-fig-0001}

3.3. Subgroup analyses of the associations between *IL‐6* polymorphisms and CAD risk {#jcmm15246-sec-0013}
------------------------------------------------------------------------------------

Subgroup analyses were introduced to identify the source of heterogeneity and further reveal additional information about the associations between *IL‐6* polymorphisms and CAD risk. Table [2](#jcmm15246-tbl-0002){ref-type="table"} summarizes the results of the subgroup analyses based on HWE, region, ethnicity, the source of controls and sample size.

For the subgroup in accordance with HWE, significant associations were only detected for the *IL‐6* rs1800796 polymorphism, and all five genetic models indicated strong associations with an increased OR compared with the pooled OR: allelic (OR \[95% CI\] = 1.32 \[1.15, 1.53\], *P* = 2^\*^10^−4^), dominant (OR \[95% CI\] = 1.42 \[1.19, 1.69\], *P* = 2^\*^10^−4^), recessive (OR \[95% CI\] = 1.48 \[1.15, 1.91\], *P* = 2^\*^10^−4^), heterozygote (OR \[95% CI\] = 1.33 \[1.14, 1.55\], *P* = 2^\*^10^−4^) and homozygote (OR \[95% CI\] = 1.78 \[1.28, 2.47\], *P* = .001) genetic models.

In the analysis of the rs1800795 polymorphism stratified by region, significant associations with reduced heterogeneity in the Asian population were observed in the dominant (OR \[95% CI\] = 1.36 \[1.17, 1.58\], *P* = 2^\*^10^−4^), recessive (OR \[95% CI\] = 1.44 \[1.16, 1.78\], *P* = .001) (Figure [2A](#jcmm15246-fig-0002){ref-type="fig"}), heterozygote (OR \[95% CI\] = 1.29 \[1.13, 1.48\], *P* = 2^\*^10^−4^) and homozygote (OR \[95% CI\] = 1.66 \[1.26, 2.19\], *P* = 2^\*^10^−4^) genetic models. In addition, decreased risks for the African population were remarkably identified in the allelic (OR \[95% CI\] = 0.45 \[0.26, 0.77\], *P* = .004) and recessive (OR \[95% CI\] = 0.29 \[0.17, 0.50\], *P* = 2^\*^10^−4^) genetic models. Regarding the rs1800796 polymorphism, all five genetic models suggested a strong relationship with CAD risk in Asian volunteers (allelic: OR \[95% CI\] = 1.30 \[1.15, 1.47\], *P* = 2^\*^10^−4^; dominant: OR \[95% CI\] = 1.36 \[1.17, 1.58\], *P* = 2^\*^10^−4^; recessive: OR \[95% CI\] = 1.44 \[1.16, 1.78\], *P* = .001 (Figure [2B](#jcmm15246-fig-0002){ref-type="fig"}); heterozygote: OR \[95% CI\] = 1.29 \[1.13, 1.48\], *P* = 2^\*^10^−4^; and homozygote: OR \[95% CI\] = 1.66 \[1.26, 2.19\], *P* = 2^\*^10^−4^). Along with region as a geographic factor, ethnicity is also an important factor. In the Caucasian population, no association was observed for the rs1800795 polymorphism, but significant associations were widely observed with the rs1800796 polymorphism in all five genetic models (allelic: OR \[95% CI\] = 1.33 \[1.17, 1.50\], *P* = 2^\*^10^−4^; dominant: OR \[95% CI\] = 1.38 \[1.19, 1.59\], *P* = 2^\*^10^−4^; recessive: OR \[95% CI\] = 1.54 \[1.23, 1.93\], *P* = .001; heterozygote: OR \[95% CI\] = 1.30 \[1.14, 1.47\], *P* = 2^\*^10^−4^; homozygote: OR \[95% CI\] = 1.78 \[1.34, 2.36\], *P* = 2^\*^10^−4^). Regarding the Mongoloid population, significant associations were observed in the dominant (OR \[95% CI\] = 1.47 \[1.31, 1.65\], *P* = 2^\*^10^−4^), recessive (OR \[95% CI\] = 2.07 \[1.72, 2.50\], *P* = 2^\*^10^−4^), heterozygote (OR \[95% CI\] = 1.28 \[1.11, 1.49\], *P* = .001) and homozygote (OR \[95% CI\] = 2.28 \[1.87, 2.77\], *P* = 2^\*^10^−4^) genetic models that implied a strong association between CAD risk and the *IL6* rs1800795 polymorphism.

![A, IL‐6 rs1800795 polymorphism (Recessive genetic model). B, IL‐6 rs1800796 polymorphism (Recessive genetic model)](JCMM-24-6191-g002){#jcmm15246-fig-0002}

In the subgroup analysis stratified by source of controls, significant associations were observed between CAD risk in the hospital‐based population and the rs1800795 polymorphism (recessive: OR \[95% CI\] = 1.46 \[1.10, 1.94\], *P* = .009) and the rs1800796 polymorphism (allelic: OR \[95% CI\] = 1.30 \[1.16, 1.47\], *P* = 2^\*^10^−4^; dominant: OR \[95% CI\] = 1.39 \[1.19, 1.61\], *P* = 2^\*^10^−4^; recessive: OR \[95% CI\] = 1.42 \[1.16, 1.74\], *P* = .001; heterozygote: OR \[95% CI\] = 1.31 \[1.14, 1.50\], *P* = 2^\*^10^−4^; and homozygote: OR \[95% CI\] = 1.70 \[1.29, 2.24\], *P* = 2^\*^10^−4^).

We stratified studies into three subgroups by sample size based on the modified quality scale score (less than 300, between 300 and 500, and greater than 500) to evaluate the effect of sample size on the associations between the two polymorphisms and CAD risk. In the greater than 500 subgroup, significant associations were observed between the rs1800795 polymorphism and CAD risk (dominant: OR \[95% CI\] = 1.37 \[1.17, 1.59\], *P* = 2^\*^10^−4^; recessive: OR \[95% CI\] = 1.95 \[1.42, 2.67\], *P* = 2^\*^10^−4^; heterozygote: OR \[95% CI\] = 1.22 \[1.06, 1.40\], *P* = .004; and homozygote: OR \[95% CI\] = 1.22 \[1.06, 1.40\], *P* = 2^\*^10^−4^); for the rs1800796 polymorphism, a significant association was only observed in the allelic genetic model (OR \[95% CI\] = 1.21 \[1.05, 1.39\], *P* = .008). We discovered that a larger sample produced more significant associations with the two polymorphisms.

3.4. The sensitivity analysis of *IL‐6* polymorphisms and CAD risk {#jcmm15246-sec-0014}
------------------------------------------------------------------

A sensitivity analysis was conducted by sequentially omitting each individual study to detect the effect of each study on the results of the overall meta‐analysis. None of the studies changed the corresponding pooled ORs; thus, the results of our meta‐analysis were stable and reliable (Figure [3A‐B](#jcmm15246-fig-0003){ref-type="fig"}).

![A, Sensitivity analysis of IL‐6 rs1800795 polymorphism (Recessive genetic model). B, Sensitivity analysis of IL‐6 rs1800796 polymorphism (Recessive genetic model). C, Begg\'s funnel plot of IL‐6 rs1800795 polymorphism (Recessive genetic model). D, Begg\'s funnel plot of IL‐6 rs1800796 polymorphism (Recessive genetic model)](JCMM-24-6191-g003){#jcmm15246-fig-0003}

3.5. Publication bias {#jcmm15246-sec-0015}
---------------------

The *P* values for the Egger\'s test of the *IL‐6* rs1800795 and rs1800796 polymorphisms were .459 and .114, respectively; in addition, Begg\'s funnel plots of the two polymorphisms were symmetrical and all *P* values were greater than .05, indicating a lack of publication bias (Figure [3C‐D](#jcmm15246-fig-0003){ref-type="fig"}).

3.6. Trial sequential analysis {#jcmm15246-sec-0016}
------------------------------

A previous meta‐analysis of the associations between *IL‐6* polymorphisms and CAD risk reported negative results. For our pooled analysis of *IL‐6* rs1800795 and rs1800796 polymorphisms, significant associations were only observed for the *IL‐6* rs1800796 polymorphism. Hence, a trial sequential analysis was required to verify that our significant association was not a false‐positive result. Similar strength associations were discovered in five different genetic models. The allelic genetic model produced the best value and is a natural model of inheritance with a stronger genotype‐phenotype association, which also does not pre‐assume any interactions between the numbers of variant alleles. Therefore, we chose the allelic genetic model of the rs1800796 polymorphism to conduct the trial sequential analysis. The results of trial sequential analysis are shown in Figure [4](#jcmm15246-fig-0004){ref-type="fig"}. The x‐axis and y‐axis represent the number of patients and the cumulative Z score, respectively. Within the designed assumptions of confidence and effect size, the information size for the *IL‐6* rs1800796 polymorphism is 24 788, and the Z curves not only cross the statistical significance line (Z = 1.96, *P* = .05), but also cross the O' Brien Fleming boundaries, indicating that the significance level of our study was a true‐positive result and the previously reported negative association was due to a lower number of volunteers.

![IL6 rs1800795 polymorphism (Pooled population, allelic genetic model)](JCMM-24-6191-g004){#jcmm15246-fig-0004}

3.7. Bioinformatics analysis {#jcmm15246-sec-0017}
----------------------------

Based on the genomic context obtained from the Ensembl database, we constructed the summary genetic diagram for the rs1800795 and rs1800796 polymorphisms (Figure [5A](#jcmm15246-fig-0005){ref-type="fig"}). The two polymorphisms were both located in the promoter region near exon 2, implying that these sequences are potential transcription factor binding sites. Hence, we analysed the sequences of the two polymorphisms and the results from the SNPinfo database showed both polymorphisms are located in potential transcription factor binding sites (Figure [5B](#jcmm15246-fig-0005){ref-type="fig"}). In addition, the secondary structure of DNA at the rs1800795 and rs1800796 sequences was predicted using RNAfold. The minimum free energy (MFE) and the free energy of the thermodynamic ensemble (FETE) of the rs1800795 polymorphism were −142.50 kcal/mol and −170 kcal/mol for the wild G allele, and 141.60 kcal/mol and 169.58 kcal/mol for the mutant C allele, respectively. For the 1800796 polymorphism, the MFE and RFTE were −136.10 kcal/mol and −162.81 kcal/mol for the wild C allele, and −133.80 kcal/mol and −162.57 kcal/mol for the mutant G allele. Based on the predicted free energy of the two polymorphisms, the secondary structure of the two polymorphisms was determined. Compared with the wild allele, the mutant alleles of both polymorphisms caused a structure change, which were pointed with arrows in Figure [6](#jcmm15246-fig-0006){ref-type="fig"}.

![A, The genetic structure of IL‐6 gene. B, The most related Transcription Factor Binding Sites predicted by SNP ratio](JCMM-24-6191-g005){#jcmm15246-fig-0005}

![The RNAfold analysis of the IL‐6 polymorphisms](JCMM-24-6191-g006){#jcmm15246-fig-0006}

4. DISCUSSION {#jcmm15246-sec-0018}
=============

In our study, two polymorphisms (rs1800795 and rs1800796) in the *IL‐6* gene were analysed for associations with CAD risk. The two common polymorphisms have been extensively studied in depth over the past few decades, providing sufficient enough data for a subgroup analysis designed to discover potential intriguing associations. Moreover, the two polymorphisms are located in the promoter region of the *IL‐6* gene, and may influence the expression of the *IL‐6* gene, and result in susceptibility to CAD. Several meta‐analyses have been conducted to explore the associations between the two polymorphisms and CAD risk, but the results were inconsistent. Significant associations between the *IL‐6* rs1800795 polymorphism and CAD risk were reported in some meta‐analyses,[^57^](#jcmm15246-bib-0057){ref-type="ref"}, [^58^](#jcmm15246-bib-0058){ref-type="ref"}, [^59^](#jcmm15246-bib-0059){ref-type="ref"} but not in the latest meta‐analysis reported by Liu et al[^60^](#jcmm15246-bib-0060){ref-type="ref"} Interestingly, the opposite result was obtained for the *IL‐6* rs1800796 polymorphism. The most recent studies by Song et al[^61^](#jcmm15246-bib-0061){ref-type="ref"} and Hou et al[^57^](#jcmm15246-bib-0057){ref-type="ref"} reported that this polymorphism may decrease the risk of CAD, which contradicts the conclusions of most previous meta‐analysis.[^59^](#jcmm15246-bib-0059){ref-type="ref"}, [^60^](#jcmm15246-bib-0060){ref-type="ref"}, [^62^](#jcmm15246-bib-0062){ref-type="ref"} We comprehensively reviewed these two studies and found that the opposite results may due to the relatively small sample size. Additionally, the adjusted alpha was not used to adjust for multiple tests, and thus, that conclusion that the result was a true positive is questionable. The controversial results from previous meta‐analysis and case‐control studies prompted us to examine the associations between the *IL6* rs1800795 and rs1800796 polymorphisms and CAD risk. Therefore, we chose these two common polymorphisms in the *IL6* gene to analyse the potential CAD risk.

No association between the *IL‐6* rs1800795 polymorphism and CAD risk with high heterogeneity was observed in the pooled results. Hence, we employed a detailed subgroup analysis to determine the potential sources of heterogeneity and associations. For the subgroup analysis stratified by region, significant associations with reduced heterogeneity were observed in the Asian population, which indicated an increased CAD risk for the rs1800795 polymorphism. Interesting results emerged in the analysis of the African subgroup and the decreased CAD risk for the mutant C allele and CC genotype were observed compared with the wild G allele and GC+CC genotypes, respectively. However, only three studies were included in the analysis of the African subgroup, and thus, we are sceptical about the conclusions and further studies are required. Similar findings were obtained for the Asian population. When stratified by ethnicity, the increased CAD risks for the rs1800795 polymorphism were observed in the Mongoloid population. The studies in the Mongoloid subgroup were performed in China, indicating that Chinese patients carrying the rs1800795 polymorphism would exhibit an increased risk of CAD. Moreover, high heterogeneity was significantly reduced when volunteers were stratified by region and ethnicity, indicating that these two factors are potential sources of high heterogeneity for the rs1800795 polymorphism. Sample size plays an important role in interpreting the conclusions of a case‐control study; thus, we conducted an analysis of subgroups stratified by sample size and discovered the increased CAD risk for the rs1800795 polymorphism in the larger sample size group. Therefore, if additional well‐designed studies are conducted, a lager sample size is required. The *IL‐6* rs1800796 polymorphism is associated with an increased risk of CAD. Extensive associations with an increased risk of CAD were observed in the pooled analysis and subgroup analyses. In addition, the trial sequential analysis confirmed the true‐positive results for the rs1800796 polymorphism, indicating that carriers of the rs1800796 mutant G allele are likely predisposed to CAD.

Coronary atherosclerosis is the main pathophysiological process in coronary artery disease, and inflammation plays a predominant role in atherosclerosis. As an important pro‐inflammatory cytokine, IL‐6 has been proven to be an independent risk factor for coronary artery disease and is expressed at relatively high levels in human atherosclerotic plaques.[^63^](#jcmm15246-bib-0063){ref-type="ref"}, [^64^](#jcmm15246-bib-0064){ref-type="ref"}, [^65^](#jcmm15246-bib-0065){ref-type="ref"} Considering the vital role of IL‐6 in atherosclerosis, the mechanism responsible for producing IL‐6 is a pivotal question. Researchers have not clearly determined whether polymorphisms in the *IL‐6* gene may also be an answer to this question. We conducted a bioinformatics analysis to predict the potential molecular mechanism. The two polymorphisms are located in the promoter region of the *IL‐6* gene, implying that the underlying mechanism occurs at the transcriptional level. The analysis of the SNPinfo database revealed potential transcription factor binding sites in the two polymorphisms, indicating the ability of these two polymorphisms to alter the expression of the *IL‐6* gene. In addition, an analysis of the sequence and secondary structure was performed using the RNAfold web server. The minimum free energy (MFE) and the free energy of the thermodynamic ensemble of the mutant alleles of the rs1800795 and rs1800796 polymorphisms were reduced compared with the wild alleles. The principle of minimum energy states that for a closed system, with constant external parameters and entropy, the internal energy will decrease and approach a minimum value at equilibrium.[^66^](#jcmm15246-bib-0066){ref-type="ref"} The mutant allele in a gene sequence may alter the free energy. The minimum free energy and the free energy of the thermodynamic ensemble are two thermodynamics parameters that have been used as a measure the required energy to reach the equilibrium for the stability of a sequence.[^23^](#jcmm15246-bib-0023){ref-type="ref"} The reduction implies that less energy is needed to form the secondary structure of the sequence containing the mutant allele, indicating that the sequence of the mutant alleles of the rs1800795 and rs1800796 polymorphisms is easier to disperse from the DNA double helix structure to serve as the template strand during transcription. Hence, these structural changes may affect the expression of the *IL‐6* gene. However, a bioinformatics prediction is not sufficient, and further fundamental research on the effect of the two polymorphisms on the transcription of the *IL6* gene is needed.

Several limitations existed in our study. First, only English and Chinese articles were included as a language restriction, which may bias the results. Second, the number of included studies was relatively small in some subgroups, such as the African population in the subgroup analysis of the *IL‐6* rs1800795 polymorphism, and thus, the results should be interpreted with caution. Third, only two common SNPs were evaluated in our study and other relevant SNPs in the *IL‐6* gene that are unknown or understudied may also have potential associations with CAD risk. Forth, the distance between the two common polymorphisms is relatively close, and the potential interactions between the two polymorphisms or other unknown polymorphisms need to be studied. In addition, the potential influence of environmental factors on genotype‐CAD associations is worth considering.

In conclusion, the *IL‐6* rs1800796 polymorphism is associated with an increased susceptibility to CAD and is a risk factor for CAD. In addition, the *IL‐6* rs1800795 polymorphism is associated with an increased risk of CAD in Asian, particularly in Chinese volunteers. Remarkably, a decreased risk of CAD was observed in the African population.

CONFLICT OF INTEREST {#jcmm15246-sec-0020}
====================

The authors confirm that there are no conflicts of interest.

AUTHOR CONTRIBUTION {#jcmm15246-sec-0021}
===================

Shuai Lu, Ya Wang and Zhaohui Wang wrote the main manuscript text. Yijun Wang and Shuai Lu prepared Figures 1 and 2. Wenhan Ma and Jing Hu prepared Figures 3 and 4. Shuangye Liu, Di Wu and Xiaohui Zeng draw the Figures 5 and 6. Yijun Wang made the Table 1. Shuai Lu, Ya Wang and Yijun Wang forged the Table 2. Guo Yu performed the statistical analysis of evaluating the strengths of associations between these two polymorphisms and CAD risk. Zhaohui Wang hosted the meeting addressing the disagreements. All authors reviewed and revised the manuscript.

Supporting information
======================

###### 

Table S1

###### 

Click here for additional data file.

###### 

Table S2

###### 

Click here for additional data file.

This work is supported by grants from the National Natural Science Foundation of China (Nos. 81170205). The funder, Zhaohui Wang, was responsible for the article.

DATA AVAILABILITY STATEMENT {#jcmm15246-sec-0023}
===========================

All data included in this study are available upon request by contact with the corresponding author.
